The gut microbiota might perhaps one day become a routine tool for the early diagnosis of many diseases and to guide treatment, but at present there is a lack of solid scientific evidence to support these claims.
Pharmalittle: We’re reading about GLP-1 spending, biosimilar patient costs, and more
Hello, everyone, and welcome to the middle of the week. Congratulations on making it this far. It is, after all, an accomplishment worth noting. And
April 24, 2024